GlassScriptPhysician profile
Anastasios Angelo Pappas
NPI 1912904970
$2,408.38
in general payments reported to CMS, 2019-2025
19 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.66 · 2020: $36.92 · 2021: $47.45 · 2022: $44.76 · 2023: $13.32 · 2024: $138 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,750 · Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,750.00 |
| Food and Beverage | $477.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,775.23 | 2021-2025 | Tremfya |
| Axsome Therapeutics, INC. | $121.14 | 2025 | Auvelity |
| Leo Pharma INC. | $87.80 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $85.22 | 2022-2025 | Dupixent |
| Genzyme Corporation | $63.74 | 2024-2025 | |
| Lilly USA, LLC | $58.17 | 2020-2024 | Ebglyss |
| Mimedx Group, INC. | $27.93 | 2025 | |
| Biowound Solutions, INC. | $21.52 | 2025 | Bio-Connekt |
| Stimlabs LLC | $21.22 | 2025 | Corplex P |
| Tactile Systems Technology INC | $19.21 | 2025 | Flexitouch Plus, Nimbl |
| Reprise Biomedical, INC. | $18.85 | 2025 | Miro 3d |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.99 | 2019 | |
| Kerecis Limited | $15.46 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Dermavant Sciences, INC. | $14.96 | 2024 | Vtama |
| Organogenesis INC. | $14.79 | 2025 | Via Matrix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $14.61 | 2020 | |
| Biofrontera INC. | $14.36 | 2021 | |
| Incyte Corporation | $12.51 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $5.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anastasios Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.